This Patent Describes HemoVoid™ To Uncover Proteomic Changes from Autologous Blood-doping
MONMOUTH JUNCTION, NJ, January 15, 2021 — Biotech Support Group reports on a patent application describing the simplicity and efficiency of their hemoglobin depletion technology for human stored red blood cells. The citation is:
Christer, M. A. L. M., et al. “Methods for the detection of autologous blood-doping.” U.S. Patent Application No. 16/976,936.
The patent application relates to the identification of peptides, and the corresponding proteins, that can be used in methods for the detection of autologous blood doping. More specifically, the invention relates to methods comprising tryptic digestion of samples of isolated red blood cell (RBC), specifically isolated RBC cytosol, followed by peptide mapping using liquid chromatography tandem-mass spectroscopy (LC-MS/MS). The invention’s description states “Hemoglobin depletion was performed using HemoVoid resin, buffers and filter tubes as described by the manufacturer (Biotech Support Group) using a standard bench-top centrifuge.”. Upon the preferable depletion of hemoglobin, the methods enable detection of increased levels of certain peptides in samples from subjects that have been subjected to autologous blood doping, compared to samples from non-doped control subjects.
“There is great interest in understanding the proteomic changes in red cells upon storage or in disease states. Being able to quantify these changes using LC-MS/MS is very important to help testing for autologous blood-doping and possibly other conditions. As this patent application describes, proteomic analysis is a very productive way to uncover and measure these important changes. I am pleased that our Hemo-Void™ product is proving to be quite useful for these purposes” states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.
To buy HemoVoid™ at Gentaur
For more information on all of our Hemoglobin Removal Products, visit:
About Biotech Support Group LLC
Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets.
Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients.
For Poland contact Gentaur
Fo Spain contact Gentaur Spain